PSNL Stock Alert: Halper Sadeh LLC is Investigating Whether Personalis, Inc. is Obtaining a Fair Price for ShareholdersBusiness Wire • 07/20/26
Shareholder Alert: Ademi LLP investigates whether Personalis, Inc. is obtaining a Fair Price for Public ShareholdersPRNewsWire • 07/20/26
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology PlatformBusiness Wire • 07/20/26
Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great BritainBusiness Wire • 07/14/26
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection KitsBusiness Wire • 06/09/26
Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors?The Motley Fool • 06/04/26
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026Business Wire • 06/02/26
Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx ConsortiumBusiness Wire • 05/26/26
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment MonitoringBusiness Wire • 05/20/26
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid TumorsBusiness Wire • 05/13/26
Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026Business Wire • 04/21/26